Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Scientists at the University of Osaka have cracked open a key mystery of immune memory: why IgG1 antibodies outlast their IgM counterparts. Using a mouse model, they found that IgG1-producing cells multiply more readily, resist cell death, and migrate more efficiently to the bone marrow — where they can keep producing antibodies for years. The findings could guide the development of longer-lasting vaccines.
Not all antibodies are created equal. Some fade within weeks of an infection, while others stick around for years. Researchers at the University of Osaka have now pinpointed exactly why IgG1 antibodies — a subclass closely linked to long-term immune protection — tend to outlast IgM antibodies, the type the immune system produces first.
Using a mouse model, the team traced the journey of B cells (the immune cells that make antibodies) from early infection through to their final home in the bone marrow. They found that IgG1-producing cells have a triple advantage: they're better at activating T cells early on, they're more resistant to apoptosis (the body's natural cell-culling process), and they migrate to the bone marrow more efficiently — where they can survive and produce antibodies for years.
Key Takeaways:
Why it matters: Understanding the biological edge that IgG1 cells hold over IgM cells opens a promising new avenue for vaccine design — potentially helping scientists engineer vaccines that trigger more durable immune responses from the start.
